Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – An Exploratory Analysis of the Proxa-Rescue AndroCoV Trial

    July 2021 in “ bioRxiv (Cold Spring Harbor Laboratory) ”
    Ricardo Ariel Zimerman, Daniel do Nascimento Fonseca, Michael do Nascimento Correia, Renan Nascimento Barros, Dirce Costa Onety, Karla Cristina Petruccelli Israel, Emilyn Oliveira Guerreiro, José Erique Miranda Medeiros, Raquel Neves Nicolau, Luiza Fernanda Mendonça Nicolau, Rafael Xavier Cunha, Maria Fernanda Rodrigues Barroco, Patrícia Souza da Silva, Raysa Wanzeller de Souza Paulain, Claudia Elizabeth Thompson, Andy Goren, Carlos Gustavo Wambier, Flavio Cadegiani
    TLDR Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.
    The study explored the effects of proxalutamide, a non-steroidal antiandrogen, on the 28-day mortality rate of hospitalized COVID-19 patients. In a randomized clinical trial with 580 participants, those who completed a 14-day proxalutamide treatment had a significantly lower mortality rate of 4.2% compared to 49.0% in the placebo group. The study found that treatment adherence was crucial, as early interruption of proxalutamide led to a high mortality rate of 79.3%. The results suggested that ensuring treatment compliance could enhance the drug's efficacy in reducing mortality among COVID-19 patients.
    Discuss this study in the Community →

    Research cited in this study

    11 / 11 results

    Related Community Posts Join

    3 / 3 results

    Similar Research

    5 / 28 results